Navigation Links
New drug candidate reduces blood lipids
Date:3/10/2010

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

High cholesterol levels in the blood are primarily treated with a group of drugs called statins, but they are not always sufficiently effective and higher doses commonly cause adverse reactions. A team of researchers, including scientists from Karolinska Institutet, have now shown in a clinical trial that a new drug substance called eprotirome can reduce blood cholesterol effectively in patients who have already received statins. Patients who were given supplementary medication with eprotirome demonstrated levels of harmful blood fats that were up to 30 per lower than those of patients who received a placebo supplementary treatment.

The trial lasted three months and included a total of 189 patients. It remains to be studied whether the drug candidate will be equally safe and effective for a larger group of patients over a longer period of time.

"This drug could help patients who react adversely to statins or be used as a supplementary treatment for those who don't respond well to them," says Professor Bo Angelin, who led the study.

Eprotirome mimics the natural ability of thyroid hormone to stimulate the metabolism of cholesterol, and exerts its effects exclusively on the liver. The development of similar non-selective drugs has previously been stopped on account of the serious adverse effects they have had on other organ systems (e.g. cardiac dilatation and osteoporosis) or on the physiological regulation of thyroid hormones.

Eprotirome has been developed by pharmaceutical company KaroBio in Huddinge, which is financing and participating in the research.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated
4. Candidate Potential Report Reduces Risk of Bad Hires
5. Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology
6. Pitt researchers find candidates for new HIV drugs
7. AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
10. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
11. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... Ohio (PRWEB) , ... December 09, 2016 , ... ... of miniature, folded, pharmaceutical inserts and outserts. As a means of expanding ... This addition will enable Flottman to individually code professional inserts (PIs) and patient ...
(Date:12/9/2016)... Yorktown Heights, NY (PRWEB) , ... December 09, 2016 , ... ... on Alcoholism and Drug Dependence, Inc. (NCADD) is recommending the film Whispering ... 29 states and the District of Columbia as an education tool in the war ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... An inventor ... amputees to safely ride all types of amusement park rides. , The patent-pending SAFETY ... unit is easy to use and could be set up in a matter of ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
Breaking Medicine Technology: